Wonju Christian Hospital   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Wonju Korea, Republic of (1959)

Organization Overview

First Clinical Trial
2008
NCT00922480
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Institutional Review Board of Wonju Severance Christian Hospital | Wonju Severance Christian Hospital | Wonju Sevrerance Christian Hospital, Wonju, Kangwon-do, Republic of

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ascites (Phase 4)

Asthma (Phase 4)

Coronary Artery Disease (Phase 4)

Crohn Disease (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Neuropathies (Phase 1)

Encephalitis (Phase 3)

Encephalitis, Japanese (Phase 3)

Essential Hypertension (Phase 3)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis B (Phase 3)

Hepatitis B, Chronic (Phase 3)

Hepatitis, Chronic (Phase 3)

Hypertension (Phase 4)

Influenza, Human (Phase 3)

Lung Diseases (Phase 3)

Lung Diseases, Obstructive (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 2)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Neuralgia (Phase 1)

Pancreatic Neoplasms (Phase 3)

Prostatic Neoplasms (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 26
  • # of Trial APIs: 41